Upstate Active Clinical Trials

Study Title:

A Phase 1B, Multicenter, Open-Label, Dose-Escalation Study to Evaluate the Safety Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered Mosentuzumab to Participants with Systemic Lupus Erythemastosus. GA43191

Upstate Institutional Review Board (IRB) Number:

1821375

Study/Protocol ID:

GA43191

Patient Age Group:

Adults

Principal Investigator:

Andras Perl, MD, PhD

Who can I contact for more information?

Name: Joanne M Chilton, CCRP
Phone: 315-464-8240
Email: chiltonj@upstate.edu

Return to Previous Page || Search Again